11
Kryszynska YT, Sherratt HSA.
The effects of 2-(6-(4-chlorophenoxy)hexyl)oxirane-2-carboxylate (etomoxir) on glucose turnover in fasted rats. Biochem. Soc. Trans. 14 (1986) 699-700.

12
Kryszynska YT, Home PD, Sherratt HAS.
The Effects of a New Hypoglycaemic and Antiketogenic Agent on Glucose Metabolism in the Rat. Diabetologia 29 (1986) No. 8, 560 A – 561 A.

13
Bliesath H, Haupt E, Luehmann R, Hoppe FU, Radtke HW.
First Administration of Etomoxir to Type 2 (Non-Insulin-Dependent) Diabetic Patients. Diabetologia 30 (1997) No. 7, 501 A.

14
Declercq PE, Falck JR, Kuwajima M, Tyminski H, Foster DW, McGarry JD.
Charcacterization of the Mitochondrial Carnitine Palmitoyltransferase Enzyme System. I. Use of inhibitors. J. Biol. Chem. 262 (1987) 9812-9821.

15
Huber R, Sturm E, Junker A, Mueller W, Nell G, Dittmann B, Kummer M, Weinges KF.
Pharmacokinetics of the new antidiabetic drug Etomoxir in man after administration of the unlabelled or 14-C-labelled compound. Proceedings of the 3rd European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, Germany 1987.

16
Kryszynska YT, Sherratt HSA.
Glucose kinetics during acute and chronic treatment of rats with 2(6(4-chlorophenoxy)hexyl) oxirane-2-carboxylate, Etomoxir. Biochem. Pharmacol. 36 (1987) 3917-3921.

17
Pégorier JP, Duée PH, Girard JR.
Contribution of Hepatic Fatty Acid Oxidation and Exogenous Galactose Supply to the Regulation of Glucose Homeostasis in the Newborn Rabbit. Biol. Neonate 51 (1987) 31-39.

18
Rothenberg RJ.
Inhibition of rabbit synoviocyte phospholipase A2 activity. American Rheumatism Association, 51st Annual Scientific Meeting, Washington, D.C. 1987, Abstract.

19
Selby PL, Bartlett K, Sherratt HAS, Alberti KGMM.
Prolonged Inhibition of Ketogenesis in Man by Etomoxir. Diabetologia 30 (1987) No. 7, 581 A.

20
Sturm E, David M, Hartig-Beecken J, Junker A.
Biotransformation pathways of Etomoxir in rat, dog and man. Proceedings of the 3rd European Congress of Biopharmaceutics and Pharmacokinetics, Freiburg, Germany 1987.